Adoption of artificial intelligence (AI) is growing rapidly in the financial services sector, as organizations all seek to benefit from the advantages brought about by the technology, including streamlined processes,

The post Over a Quarter of Banks Report Improved Revenue After Implementing AI appeared first on Fintech Singapore.

Billpay platform doxo has raised $18.5 million in Series C funding. The round was led by Jackson Square Ventures and featured participation from existing investors. Headquartered in Seattle, Washington, doxo will use the capital to grow its platform and expand its team. In a round led by Jackson Square Ventures, billpay platform doxo has secured Read more...

The post Billpay Innovator doxo Raises $18.5 Million in Series C Funding appeared first on Finovate.

Although the Bank of Canada still has no plans to issue a Central Bank Digital Currency, it has accelerated its research on such a project. (Read More)

The total value locked (TVL) on the Cardano network has soared past $270 million since the beginning of the year. ...

Read More...

DOGE and SHIB continue their week-long market slump with their price actions remaining in the deep red as we can see more today in our latest altcoin news. The dog-themed coins DOGE And SHIB continue their market slump as Dogecoin is down by 6% over the past week and trading at over $0.11, down by […]

The world’s first playable AAA NMO web3 game, Delysium has closed its first round of private sale. The sale, which was led by top investors Galaxy Interactive, Republic Crypto, and Alameda Research, ended with $4 million raised, which will be used mainly to support the game production and ecosystem. The game is led by RCT […]

Los Angeles, USA, 14th March, 2022, Chainwire   Delysium has completed its first round of private-sale of over $4 million, led by Galaxy Interactive, Republic Crypto, and Alameda Research, with Anthos Capital, Eureka Meta Capital, Y2Z Ventures, Tess Ventures, Zonff...

As we venture into the year 2022, Proof of Reserves is emerging from a niche concept into a fledgling industry standard.

Binance Coin (BNB) is the native token of the Binance blockchain. The Binance blockchain allows developers and project owners to create decentralized applications (dApps) on it. Most of the dApps that are developed in the Binance blockchain are hosted as BEP20 tokens which are in their thousands. Presently, transactions in the tokens are carried out by using ether in buying the fees in the form of BNB which is one of the cheapest in the industry. Also, recent projects are hosted on Binance Smart Chain (BSC). What is Binance Coin (BNB)? Binance Coin is a cryptocurrency that was founded by Binance exchange CEO Changpeng Zhao in 2017. BNB was formerly hosted on the Ethereum blockchain during its launch before the migration to Binance Smart Chain in September 2020 after the launch. It raised $15 million through its public sale of 100 million BNB out of its total supply of 200 million at an initial coin offering price of $0.15. BNB investors used Bitcoin and Ethereum to purchase the token during the launch. Binance Coin (BNB) has been community-driven following the ease to build and launch tokens on Binance Smart Chain. This has enabled it to attain an all-time high price of $690.93 on May 10th, 2021 during the bullish run of some of the top 50 cryptocurrencies. The early investors who purchased BNB during its ICO are presently having a return on investment worth over $3800 per $1. Let’s see the Binance Coin price analysis for the coming years. Price Analysis of Binance Coin Flashback: Fundamental Analysis of Binance Coin Fundamental analysis has to do with ways through which news and announcements can affect the price of an asset. In the Binance crypto and exchange community, there is news that has increased the positive sentiments that investors have for it in the long term. In recent news, it was announced that Binance Smart Chain and Binance Coin would now be called “Build and Build” which denotes a better symbol for BNB and will help users who wish to create tokens that they are committed to the success of the blockchain irrespective of stiff competition they face from other competitors in the industry. When more projects are launched on the Binance blockchain, the price of BNB will continue to rise as a result of more demand to carry out transactions in the platform with it. Also, there was a release that the Binance Accelerated Burn Program has enabled it to keep burning a certain quantity of BNB every quarter depending on the total blocks produced and the gas fees released, which will be replaced with the BNB auto-burn mechanism. This will ensure a hitch-free process that can be independently verified until 50% (100 BNB) of its total supply had been burned. Now, we shall use charts to discuss the price analysis of Binance Coin (Build and Build). https://www.tradingview.com/x/kQDJkz6f/ From the link above, the relative strength index (RSI) value of Binance Coin is 48.03 which means that the present trend is weak or neutral since it lies between 30 and 50. More buyer pressure might increase the price since it is currently bullish. https://www.tradingview.com/x/MdpAiudS/ The link above represents a 1day chart of BNB/USDT using the Keltner channel that helps to know the direction of a trend. Since the present candlestick is within the middle part of the curve though bullish, the price of BNB might consolidate further before taking a direction depending on the activities of buyers or sellers. https://www.tradingview.com/x/64YrwekL/ BNB might witness a period of downtrend soon since the yellow curve in the EMA Ribbon link above is above the recently formed candlesticks. Binance Coin Price Prediction 2022 By the end of the first quarter of 2022, the price of BNB might reach $390. However, it will be within the range of $340 and $410 by the end of the second quarter of 2022. By the end of the third and fourth quarters of the year 2022, BNB prices will be within $395 to $500 and $410 to $600 respectively. Binance Coin Price Prediction 2023 The price of BNB might reach $700 by the end of the first quarter and $800 by the end of the second quarter. In the third and fourth quarters of 2023, Binance Coin prices drop to $600 and then rise to $900 respectively. Binance Coin Price Prediction 2024 The price of BNB might reach $1000 by the end of the first quarter and $1200 by the end of the second quarter. In the third and fourth quarters of 2024, BNB prices might be $1600 and $1900 respectively. Binance Coin Price Prediction 2025 The price of Binance Coin might reach $1800 by the end of the first quarter and $2000 by the end of the second quarter. In the third and fourth quarters of 2025, BNB prices … Continued

The post Binance Coin Price Prediction 2022-2026-Will BNB Price Hit $600 by the end of 2022? appeared first on Cryptoknowmics-Crypto News and Media Platform.

Companies have embraced the cloud and accelerated adoption, but with insider access to infrastructure even more available, can businesses defend their expanded attack surface?

The New Zealand dollar’s mini-rally has come to a halt, as NZD/USD has posted slight losses. In the North American session, NZD/USD is trading at 0.6845, down 0.21% on the day. NZ Manufacturing PMI expands New Zealand’s manufacturing sector posted strong numbers this week. Earlier today, Manufacturing PMI accelerated to 53.6 in February, up from […]

TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations. Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which begins April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.

"Four key presentations at AD/PD 2022 advance our understanding of the mechanism of action of Eisai's investigational anti- Abeta protofibril antibody lecanemab and the therapy's clinical and safety profile, including amyloid related imaging abnormalities, or ARIA, from the Phase 2b study and open-label extension, in the potential treatment of early Alzheimer's disease," said Michael Irizarry, M.D., Senior Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "In addition to lecanemab, Eisai's robust pipeline includes compounds targeting the tau pathway, other pathways leading to neurodegeneration, and the testing of combination therapies that may be the optimal approach to treat or even prevent Alzheimer's disease."

The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease. Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.

"Because of the robust design of the lecanemab Phase 2b study, Eisai was able to design the Phase 3 confirmatory Clarity AD clinical trial to optimally verify lecanemab's clinical efficacy and safety in early Alzheimer's disease," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "Part of the recruitment strategy for the Clarity AD confirmatory trial was to ensure greater inclusion of ethnic and racial populations. While there is still important work to be done in ensuring minority populations' participation in clinical trials, Eisai is proud that approximately 25% of the total U.S. enrollment in Clarity AD consists of African American and Hispanic persons living with early Alzheimer's disease, which mirrors the U.S. Medicare population."

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit https://www.eisai.com/news/2022/news202218.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.